(S)-2-[(2,2,2-trifluoro-acetylamino)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester | 168049-31-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (S)-2-[(2,2,2-trifluoro-acetylamino)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester
• 英文别名: (S)-2-[(2,2,2-Trifluoro-ethanoylamino)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester；tert-butyl (2S)-2-[[(2,2,2-trifluoroacetyl)amino]methyl]pyrrolidine-1-carboxylate
• CAS: 168049-31-8
• 化学式: C₁₂H₁₉F₃N₂O₃
• 分子量: 296.29
• InChiKey: MCOPOJXBKPXZCR-QMMMGPOBSA-N

物化性质

• 沸点：
  354.8±42.0 °C(Predicted)
• 密度：
  1.217±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-2-[(2,2,2-trifluoro-acetylamino)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester 在 sodium hydride 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-1-boc-2-(甲基氨基甲基)-吡咯烷
  参考文献：
  名称：

  Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: Improvement of potency in vitro and in vivo

  摘要：

  We have increased the potency of imidazo[1,2-b]pyridazine derivatives as IKK beta inhibitors with two strategies. One is to enhance the activity in cell-based assay by adjusting the polarity of molecules to improve permeability. Another is to increase the affinity for IKK beta by the introduction of additional substituents based on the hypothesis derived from an interaction model study. These improved compounds showed inhibitory activity of TNF alpha production in mice. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.078
• 作为产物：
  描述：

  三氟乙酸乙酯 、 S-叔丁氧羰基-2-(氨基乙基)吡咯烷 以 四氢呋喃 为溶剂， 反应 3.08h， 以to give the expected compound (14.86 g)的产率得到(S)-2-[(2,2,2-trifluoro-acetylamino)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Pyrrolidines and piperidines as orexin receptor antagonists

  摘要：

  本发明涉及式(I)的化合物，其中Y、A、N和R1如描述中所述，以及该化合物的盐，特别是药学上可接受的盐，以及将该化合物用作药物，特别是作为促进睡眠的药物。

  公开号：

  US08288411B2

文献信息

• PYRROLIDINES AND PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Aissaoui Hamed

  公开号：US20100197733A1

  公开（公告）日：2010-08-05

  The invention relates to compounds of formula (I) wherein Y, A, N and R 1 are as described in the description, to salts, especially pharmaceutically acceptable salts, of such compounds and to the use of such compounds as medicaments, especially as orexin receptor antagonists.

  该发明涉及式（I）中的化合物，其中Y、A、N和R1如描述中所述，以及这些化合物的盐，特别是药用盐，以及将这些化合物用作药物，特别是作为促进睡眠的药物。
• 2-CYCLOPROPYL-THIAZOLE DERIVATIVES
  申请人：Aissaoui Hamed

  公开号：US20100222328A1

  公开（公告）日：2010-09-02

  The invention relates to selected 2-cyclopropyl-thiazole derivatives of the formula (I) wherein B, Y and R1 are as described in the description; to salts and especially pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.

  该发明涉及公式（I）中所述的选择性2-环丙基噻唑衍生物，其中B、Y和R1如描述中所述；以及其盐，特别是药学上可接受的盐；以及将这些化合物用作药物，特别是促觉醒素受体拮抗剂的用途。
• N-aroyl cyclic amines
  申请人：——

  公开号：US20040143115A1

  公开（公告）日：2004-07-22

  This invention relates to N-aroyl cyclic amine derivatives and their use as orexin antagonists 1 wherein: Y represents a bond, oxygen, or a group (CH 2 ) n , wherein n represents 1, 2 or 3; m represents 1, 2, or 3; p represents ) or 1; X is NR, wherein R is H or (C 1-4 )alkyl; Ar 1 is aryl, or a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S; any of which may be optionally substituted; A 2 represents phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heterocyclyl group is substituted by R 1 and further optional substituents; or Ar 2 represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 3 heteroatoms selected from N, O and S; R 1 represents hydrogen, optionally substituted (C 1-4 )alkoxy, halo, cyano, optionally substituted (C 1-6 )alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclyl group containing up to 4 heteroatoms selected from N, O and S; when Ar 1 is aryl p is not 1, or a pharmaceutical acceptable salt thereof.

  本发明涉及N-芳酰基环状胺衍生物及其作为促进睡眠荷尔蒙拮抗剂的用途，其中：Y代表键，氧或(CH2)n基团，其中n代表1、2或3；m代表1、2或3；p代表0或1；X为NR，其中R为H或(C1-4)烷基；Ar1为芳基，或含有最多3个N、O和S杂原子的单环或双环杂芳基基团，其中任何一个可以选择性地被取代；A2代表苯基或含有最多3个N、O和S杂原子的5-或6-成员杂环基团，其中苯基或杂环基团被R1和进一步可选取代基取代；或者Ar2代表一个可选择性取代的双环芳香基或双环杂芳香基团，其中含有最多3个N、O和S杂原子；R1代表氢，可选择性取代的(C1-4)烷氧基，卤素，氰基，可选择性取代的(C1-6)烷基，可选择性取代的苯基，或含有最多4个N、O和S杂原子的可选择性取代的5-或6-成员杂环基团；当Ar1为芳基时，p不为1；或其药学上可接受的盐。
• N-AROYL CYCLIC AMINES
  申请人：BRANCH Clive Leslie

  公开号：US20090029986A1

  公开（公告）日：2009-01-29

  Disclosed are N-aroyl cyclic amine derivatives having the formula: wherein the substituent variables are as defined herein, and their use as pharmaceuticals.

  揭示了具有以下公式的N-芳酰基环状胺衍生物： 其中取代基变量如此定义，并且它们作为药物的用途。
• Dpp-Iv Inhibitors
  申请人：Edwards Paul John

  公开号：US20080027035A1

  公开（公告）日：2008-01-31

  The invention relates to compounds of formula (I) wherein Z, R 1-5 , X, n, A 1 and A 2 have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  本发明涉及式（I）的化合物，其中Z，R1-5，X，n，A1和A2的含义如所述及权利要求中所述。所述化合物可用作DPP-IV抑制剂。本发明还涉及制备这种化合物以及其作为药物的生产和使用。